Abstract
No public abstract is available from the verified source records.
Alireza Shoari
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
The promise of digital health: then, now, and the future
10.31478/202206e · 2022
Bench, bedside, boardroom: negotiating translational gene therapy
10.1080/14636778.2017.1289468 · 2017
Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: umbrella review
10.1016/j.healthpol.2022.10.007 · 2022
Barriers for conducting clinical trials in developing countries- a systematic review
10.1186/s12939-018-0748-6 · 2018
Regulations in Japan
2024
Real-world evidence to support regulatory submissions: a landscape review and assessment of use cases
10.1111/cts.13903 · 2024
10.3389/fmed.2024.1408636
10.3389/fmed.2024.1408636
Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future
10.1177/2042098620938595 · 2020
Duchenne muscular dystrophy: disease mechanism and therapeutic strategies
2023
Emerging technologies and their impact on regulatory science
10.1177/15353702211052280 · 2022
International harmonization for cell and gene therapy products
10.1007/978-3-031-34567-8_14 · 2023
The horizon of gene therapy in modern medicine: advances and challenges
10.1007/5584_2019_463 · 2020
Bioethical issues in genome editing by CRISPR-Cas9 technology
10.3906/biy-1912-52 · 2020
United States food and drug administration regulation of gene and cell therapies
10.1007/978-3-319-18618-4_1 · 2015
A state-of-the-art review of registries in spinal muscular atrophy: a valuable resource for clinical research
2025
Explainable artificial intelligence (XAI): concepts, taxonomies, opportunities and challenges toward responsible AI
10.1016/j.inffus.2019.12.012 · 2020
Navigating challenges and opportunities in orphan medicines: a spotlight commentary on rare diseases
10.1002/bcp.70013 · 2025
Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer
10.1002/emmm.201200245 · 2012
Optimizing regulatory frameworks for gene therapies in rare diseases: challenges and solutions
10.1016/j.omtm.2024.101386 · 2024
Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models
10.1016/j.ghir.2008.05.005 · 2008
Strengthening health systems for access to gene therapy in rare genetic disorders
10.1016/j.omtm.2024.101220 · 2024
Onasemnogene abeparvovec: a review in spinal muscular atrophy
10.1007/s40263-022-00941-1 · 2022
Promoting inclusion in clinical trials—a rapid review of the literature and recommendations for action
10.1186/s13063-021-05849-7 · 2021
Clinical potential of microdystrophin as a surrogate endpoint
10.1016/j.nmd.2022.12.007 · 2023
Consequences of increased longevity for wealth, fertility, and population growth
10.1016/j.physa.2007.09.004 · 2008
Recent advances in genome editing and bioinformatics: addressing challenges in genome editing implementation and genome sequencing
10.3390/ijms26073442 · 2025
Advancing the future of equitable access to health care: recommendations from international health care leaders
10.1093/haschl/qxae094 · 2024
Ethics by design for artificial intelligence
10.1007/s43681-023-00330-4 · 2024
Bioethics of somatic gene therapy: what do we know so far?
10.1080/03007995.2023.2257600 · 2023
Viral vector platforms within the gene therapy landscape
10.1038/s41392-021-00487-6 · 2021
Challenges and recommendations for wearable devices in digital health: data quality, interoperability, health equity, fairness
10.1371/journal.pdig.0000104 · 2022
A catholic perspective on human gene therapy
1993
Innovation in chemistry, manufacturing, and controls—A regulatory perspective from industry
10.1016/j.xphs.2019.02.007 · 2019
A roadmap for fostering timely regulatory and ethics approvals of international clinical trials in support of global health research systems
10.1016/s2214-109x(24)00515-1 · 2025
AMA code of medical ethics’ opinions related to unrepresented patients
10.1001/amajethics.2019.600 · 2019
Rethinking the knowledge-attitudes model and introducing belief in human evolution: examining antecedents of public acceptability of human gene editing
10.1080/13698575.2022.2123903 · 2022
Stem cell therapeutics and gene therapy for neurologic disorders
10.1016/j.neurot.2024.e00427 · 2024
Gene therapy for neurodegenerative disorders: advances, insights and prospects
10.1016/j.apsb.2020.01.015 · 2020
Planning for progress: a US regulatory approach to advancing the clinical development of gene therapies
10.1016/j.ymthe.2022.05.005 · 2022
Policy advocacy and nursing organizations: a scoping review
10.1177/15271544211050611 · 2021
Development of the first World Health Organization lentiviral vector standard: toward the production control and standardization of lentivirus-based gene therapy products
10.1089/hgtb.2017.078 · doi-reference
Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged ≥4 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)
10.1002/ana.26755 · doi-reference
Regulatory reform outcomes and accelerated regulatory pathways for new prescription medicines in Australia
10.1007/s43441-022-00465-2 · doi-reference
Ethical perspectives on treatment options with spinal muscular atrophy patients
10.1002/ana.26299 · doi-reference
From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine
10.1186/s12967-024-05957-3 · doi-reference
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients
10.1186/s40035-025-00477-6 · doi-reference
Development and clinical translation of ex vivo gene therapy
10.1016/j.csbj.2022.06.015 · doi-reference
The estimated annual financial impact of gene therapy in the United States
10.1038/s41434-023-00419-9 · doi-reference
Ethical issues in the treatment of late-stage Alzheimer’s disease
10.3233/jad-180865 · doi-reference
Solving neurodegeneration: common mechanisms and strategies for new treatments
10.1186/s13024-022-00524-0 · doi-reference
Innate immune response to viral vectors in gene therapy
10.3390/v15091801 · doi-reference
Elucidating the role of artificial intelligence in drug development from the perspective of drug-target interactions
10.1016/j.jpha.2024.101144 · doi-reference
Informed consent in clinical trials
10.1016/0168-8510(95)00805-5 · doi-reference
Principles of clinical ethics and their application to practice
10.1159/000509119 · doi-reference
AI, opacity, and personal autonomy
10.1007/s13347-022-00577-5 · doi-reference
Drug delivery systems, CNS protection, and the blood brain barrier
10.1155/2014/869269 · doi-reference
Key concepts of clinical trials: a narrative review
10.3810/pgm.2011.09.2475 · doi-reference
CRISPR gene therapy: applications, limitations, and implications for the future
10.3389/fonc.2020.01387 · doi-reference
Substituted judgment: the limitations of autonomy in surrogate decision making
10.1007/s11606-008-0688-8 · doi-reference
Cell and gene therapy products: navigating the regulatory landscape of paradigm approvals in the US (2020 to 2024)
10.1007/s12247-025-09973-8 · doi-reference
Achievements and challenges of the Sakigake designation system in Japan
10.1111/bcp.14807 · doi-reference
The state of gene therapies: the FDA perspective
10.1038/mt.2012.51 · doi-reference
Gene-based therapies for neurodegenerative diseases
10.1038/s41593-020-00778-1 · doi-reference
The role of community advisory boards: involving communities in the informed consent process
10.2105/ajph.91.12.1938 · doi-reference
Ethical aspects of facilitating the recruitment of people with dementia for clinical trials: a call for further debate
10.1111/bcp.14968 · doi-reference
Precision genome editing techniques in gene therapy: current state and future prospects
10.2174/0115665232279528240115075352 · doi-reference
Immune responses to viral gene therapy vectors
10.1016/j.ymthe.2020.01.001 · doi-reference
Moving forward after two deaths in a gene therapy trial of myotubular myopathy” by Wilson and Flotte
10.1089/hum.2020.217 · doi-reference
Rules for processing genetic data for research purposes in view of the new EU general data protection regulation
10.1038/s41431-017-0045-7 · doi-reference
Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine
10.3390/pharmaceutics16101328 · doi-reference
Evolving drug regulatory landscape in China: a clinical pharmacology perspective
10.1111/cts.12987 · doi-reference
Incentives for orphan drug research and development in the United States
10.1186/1750-1172-3-33 · doi-reference
The use of N-of-1 trials to generate real-world evidence for optimal treatment of individuals and populations
10.1017/cts.2023.604 · doi-reference
Advance care planning and advance directives: an overview of the main critical issues
10.1007/s40520-021-02001-y · doi-reference
Addressing the value of gene therapy and enhancing patient access to transformative treatments
10.1016/j.ymthe.2018.10.017 · doi-reference
Real-world safety data of the orphan drug onasemnogene abeparvovec (Zolgensma®) for the SMA rare disease: a pharmacovigilance study based on the EMA adverse event reporting system
10.3390/ph17030394 · doi-reference
Risks and benefits of human germline genome editing: an ethical analysis
10.1007/s41649-018-0056-x · doi-reference
Patient advocacy organizations, industry funding, and conflicts of interest
10.1001/jamainternmed.2016.8443 · doi-reference
Using digital technologies in clinical trials: current and future applications
10.1016/j.cct.2020.106219 · doi-reference
Prevailing public perceptions of the ethics of gene therapy
10.1089/hum.2014.030 · doi-reference